{"disease":{"id":"chronic-spontaneous-urticaria-csu","name":"chronic spontaneous urticaria csu"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07021495","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","phase":"","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT06868212","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07328178","title":"Analysis of the Role of IgE Proteoforms in Health and Disease","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT07415551","title":"Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT07365683","title":"Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Derma Techno Pakistan","has_results":false},{"nct_id":"NCT07166211","title":"Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT06865651","title":"Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06795373","title":"Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ahuva D Cices","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}